China Universal Asset Management Co., Ltd.
Position in IMRX — Immuneering Corp
CIK 1906594
SHANGHAI, F4
Position in IMRX
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$63,857
+$3,474 QoQ
Shares Held
12,797
+11.7% QoQ
Ownership
0.020%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#81
of 111 holders
Holding Since
Sep 2022
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in IMRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026China Universal Asset Management Co., Ltd. holds $180,189,557 across 240 Biotechnology names. IMRX ranks #188 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
48,265 | $23,974,673 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
19,498 | $12,157,782 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
25,269 | $7,606,727 | |
| 4 | RPRX |
Royalty Pharma plc
|
120,547 | $6,759,070 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
33,835 | $6,336,618 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
76,302 | $6,049,985 | |
| 7 | MRNA |
Moderna, Inc.
|
63,149 | $4,422,324 | |
| 8 | ARGX |
Argenx SE
|
4,642 | $4,306,708 |
All Filings in IMRX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $63,857 | 12,797 | Shares | Sole | 2026-07-24 | |
| 2026-03-31 | $60,383 | 11,458 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $102,134 | 15,522 | Shares | Sole | 2026-01-29 | |
| 2025-09-30 | $35,000 | 5,000 | Shares | Sole | 2025-11-10 | |
| 2023-09-30 | $5,752 | 749 | Shares | Sole | 2024-05-22 | |
| 2023-06-30 | $3,883 | 383 | Shares | Sole | 2024-05-22 | |
| 2023-03-31 | $3,476 | 358 | Shares | Sole | 2024-05-22 | |
| 2022-12-31 | $1,299 | 268 | Shares | Sole | 2024-05-22 | |
| 2022-09-30 | $3,537 | 247 | Shares | Sole | 2022-10-21 | |
| No filing history on record for this holder in this stock. | ||||||